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ABSTRACT
Ventricular arrhythmias, including ventricular
fibrillation (VF) and sustained ventricular
tachycardia (VT), are the principal causes of
sudden cardiac death in patients with structural
heart disease. While coronary artery disease is
the predominant substrate associated with the
development of VT, these arrhythmias are
known to occur in a variety of disorders,
including dilated cardiomyopathy, valvular
and congenital heart disease, and cardiac ion
channelopathies such as the long QT syndrome.
In a minority of patients, VT occurs in the
absence of structural heart disease. Despite the
established mortality benefit of the implantable
cardioverter defibrillator (ICD) in patients at
risk of lethal arrhythmias, recurrent VT/VF
events continue to be a source of morbidity
and impaired quality of life in such patients.
Antiarrhythmic therapy is indicated in select
patients to treat symptomatic VT episodes, to
reduce the incidence of ICD shocks, and
potentially to improve quality of life and
reduce hospitalizations related to cardiac
arrhythmia. The primary adverse effects of
antiarrhythmic medications are related to both
cardiac and extracardiac toxicity, including the
risk of proarrhythmia. Current drug therapy for
ventricular arrhythmia has been limited by
suboptimal efficacy in many patients, resulting
in recurrent VT/VF events, and by drug toxicity
or intolerance leading to discontinuation in a
large percentage of patients. Amiodarone
and sotalol are the principal agents used in
the chronic treatment of VT. In addition,
dronedarone and dofetilide, agents approved
for the treatment of atrial fibrillation, and
ranolazine, an antianginal agent, have been
demonstrated to be protective against
ventricular arrhythmia in small clinical studies.
Finally, advances in basic electrophysiology have
uncovered new molecular targets for the
treatment of ventricular arrhythmia, and
pharmacologic agents directed at these targets
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may emerge as promising VT treatments in the
future. The roles of these current and emerging
therapies for the treatment of VT in humans will
be summarized in this review.
Keywords: Antiarrhythmic medications;
Ventricular fibrillation; Ventricular tachycardia
INTRODUCTION
Ventricular arrhythmias, including ventricular
tachycardia (VT) and ventricular fibrillation (VF),
are the leading cause of sudden cardiac death
(SCD), which in turn represents about half of all
cardiovascular mortality and accounts for over
350,000 deaths annually in the United States [1].
VT can be either sustained (lasting [30 s)
or nonsustained, and can have a uniform QRS
morphology (monomorphic) or a variable
morphology (polymorphic). It is the most
common wide complex tachycardia seen in
association with structural heart disease [2]. The
vast majority of VT is related to myocardial
pathologic processes that promote cardiac
fibrosis or inflammation, most commonly from
coronary artery disease (CAD) in over 80%
of patients [3]. However, myocarditis, dilated
cardiomyopathy, congenital heart disease,
cardiac infiltrative diseases, arrhythmogenic
right ventricular cardiomyopathy, and
hypertrophic cardiomyopathy are also known
to contribute to an arrhythmogenic substrate. In
about 10% of patients, VT occurs in the absence
of structural heart disease [4]. This subset of
VT is thought to be either idiopathic or
related to primary electrical disease, such as
the long QT syndrome, Brugada syndrome,
catecholaminergic polymorphic ventricular
tachycardia (CPVT), or other cardiac ion
channelopathies [5, 6].
The principal mechanisms of
arrhythmogenesis in the heart are abnormal
automaticity, triggered activity from after-
depolarizations, and myocardial reentry [2].
Triggered activity and abnormal automaticity
are the most important mechanisms of focal VT
arising from the ventricular outflow tracts,
although microreentrant circuits may also play
a role. In the setting of myocardial scar from
CAD, macroreentry is the most common
mechanism contributing to VT [7, 8]. It is
estimated that 1–5% of all patients with a
history of previous myocardial infarction (MI)
will develop VT. In the setting of acute MI, on
the other hand, the incidence of VT/VF ranges
from 2% to 10% [9, 10]. This upfront
arrhythmic risk has been reduced by early
coronary reperfusion strategies, such as
thrombolytics and primary angioplasty, in the
acute phases of MI [2, 11]. The electrical
substrate for VT following acute MI is
established as early as 2 weeks postinfarction,
based on programmed ventricular stimulation
studies, and presumably is present indefinitely
[12]. The abnormal substrate is characterized by
inflammation and fibrosis, cardiac hypertrophy,
abnormal cell coupling, and ion channel
expression in the myocardium that promote
ventricular arrhythmia [5]. The subsequent
development of VT in at-risk patients results
from the interplay of the abnormal myocardial
substrate and arrhythmogenic triggers. The
roles played by the autonomic nervous system,
hemodynamic stress, metabolic abnormalities,
and ventricular premature depolarizations as
proarrhythmic triggers have all been well
described [6, 13].
The only intervention demonstrated to
improve survival in patients at risk of SCD
from ventricular arrhythmias is the implantable
cardioverter defibrillator (ICD). It is indicated
for secondary prevention in patients with a
28 Cardiol Ther (2013) 2:27–46
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history of sustained VT/VF, and for primary
prevention in patients with a history of heart
failure or previous MI and left ventricular
ejection fraction (LVEF) of 35% or less [14].
There are several limitations, however, with the
ICD as primary therapy for VT/VF. First, and
most important, is that although the ICD
effectively terminates ventricular arrhythmias,
it does not prevent them. Second is the
morbidity associated with both appropriate
and inappropriate ICD shocks. Third, the
current selection criteria for ICD candidacy are
imperfect, as many ICD recipients never receive
appropriate ICD therapy for VT/VF, whereas
many other patients with LVEF greater than
35% who are not eligible for the ICD go on to
experience SCD [15]. In addition, the benefit of
the ICD is not established in the early post-MI
period; despite an increased risk of arrhythmic
death in this population, there was no
difference in total mortality in patients within
6 and 40 days of acute MI treated with the ICD
vs. medical therapy in a randomized trial [16].
Antiarrhythmic drug therapy is commonly
used as adjunctive treatment in ICD recipients for
the suppression of VT/VF episodes. In the
Antiarrhythmic Versus Implantable Defibrillator
(AVID) trial of secondary prevention ICD
therapy, the 1-year arrhythmia event rate was
90% in the ICD arm, and was reduced to 64%
with concurrent antiarrhythmic therapy [17].
Overall, up to 70% of patients with an ICD
receive adjuvant antiarrhythmic drug therapy,
even though there is no medication formally
approved for this indication [18]. The indications
for adjunctive antiarrhythmic therapy are: to
reduce the incidence of appropriate and
inappropriate ICD shocks; to slow the rate of
spontaneous VT episodes to improve their
hemodynamic tolerance and to facilitate pace
termination by the ICD; to treat symptomatic
VT episodes; to improve quality of life; and
potentially to reduce hospitalizations related to
cardiac arrhythmia [18].
Current antiarrhythmic therapy for VT is
limited by its potential for both cardiac and
extracardiac toxicity, including the risk of
proarrhythmia, and by its limited efficacy. In
the Optimal Pharmacological Therapy in
Cardioverter Defibrillator Patients (OPTIC)
trial, amiodarone and sotalol were each
significantly more effective in preventing ICD
shocks compared to beta-blockers alone, but
1-year shock rates were still 10% in the
amiodarone arm and 24% in the sotalol arm,
with drug-related adverse effects leading to
discontinuation in one in five patients [19].
No new antiarrhythmic agents have yet been
approved for the treatment for VT in the past
decade; however, novel concepts in the
understanding of ventricular arrhythmogenesis
have the potential to deliver new therapeutic
targets for VT that balance antiarrhythmic
efficacy against the risks of organ toxicity,
negative inotropy, and proarrhythmic effects
seen with contemporary drug therapy.
Several clinical trials have evaluated the
efficacy and safety of various antiarrhythmic
medications used for the treatment of VT in
patients with established cardiovascular disease.
This review will summarize their findings and
discuss more recent data on emerging
pharmacotherapies for ventricular arrhythmia.
METHODS
The following review article incorporates data
from clinical trials, review articles, and
textbooks to provide a comprehensive and up-
to-date summary of antiarrhythmic drug
therapy for VT. Emerging antiarrhythmic
therapies include those agents that have not
yet been approved for clinical use in VT but
Cardiol Ther (2013) 2:27–46 29
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have been tested in clinical investigations or




Classification of Antiarrhythmic Agents
The most common classification scheme for
antiarrhythmic agents is the Vaughan Williams
classification, which characterizes drugs based
on their ability to block specific ion currents
or cell receptors [20]. Table 1 summarizes
these agents and their use in the treatment
of ventricular arrhythmias, and Table 2
summarizes the results of select clinical trials
with these medications. Class I agents are
sodium channel blockers, further divided
into Class IA (quinidine, procainamide and
disopyramide), Class IB (lidocaine, mexiletine),
and Class IC (flecainide, propafenone). Class II
agents are beta-adrenergic receptor blockers,
such as propranolol. Class III agents are
potassium channel blockers, such as
amiodarone, sotalol, dofetilide, and
dronedarone. Class IV agents are calcium
channel blockers, such as verapamil. The
Vaughan Williams classification does not,
however, account for the complex actions of
certain antiarrhythmics, such as amiodarone,
which is known to have multichannel blocking
properties [38].
Beta-Blockers
Beta-blockers are considered first-line therapy
for patients with systolic heart failure and
following acute MI for their established
survival benefit in these populations [30, 31,
39, 40]. In addition, beta-blockers are indicated
in the treatment of certain ion channelopathies,
such as congenital long QT syndrome and CPVT
[41].
In the Cardiac Insufficiency Bisoprolol Study
II (CIBIS-II), bisoprolol reduced all-cause
mortality by 34% and sudden cardiac death by
44% in patients with heart failure [30]. The
Clopidogrel and Metoprolol in Myocardial
Infarction Trial (COMMIT) randomly assigned
over 45,000 patients to either a combination of
intravenous and oral metoprolol or placebo
within 24 h of acute MI, and showed that the
use of early beta-blocker therapy reduced the
risk of VF development, although this was
counterbalanced by an increase in cardiogenic
shock, especially during the first day after
admission [31]. Overall, a meta-analysis of
beta-blocker studies in post-MI patients
suggests a significant relative benefit in
preventing SCD and all-cause mortality [42].
Amiodarone
Amiodarone is an iodinated benzofuran
derivative that is highly lipophilic. It combines
properties of all Vaughan Williams
classifications, possessing sodium channel,
potassium channel, calcium channel, and
beta-adrenergic receptor blocking activity. It
accumulates in a variety of organ tissues,
including adipose, leading to an elimination
half-life of over 30 days. In fact, amiodarone can
be detected in plasma up to 9 months after
discontinuation [22].
In the pre-ICD era, amiodarone had an
established use for the prevention of SCD in
high-risk patients with a history of previous MI
or aborted SCD [43]. Meta-analysis showed a
modest reduction in all-cause mortality with
amiodarone vs. placebo [44]. A pooled analysis
of the European Amiodarone Myocardial
Infarction Trial (EMIAT) and the Canadian
Amiodarone Myocardial Infarction Trial
(CAMIAT) that evaluated amiodarone use in
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patients recovering from MI (EMIAT enrolled
patients with LVEF B40% and CAMIAT enrolled
patients with frequent or repetitive ventricular
ectopy) found that incidences of cardiovascular
death and arrhythmic death or resuscitated
cardiac arrest were significantly lower in
patients receiving both beta-blockers and
amiodarone than in those not receiving beta-
blockers, with or without amiodarone [34].
Conversely, in the era of the primary
prevention ICD, amiodarone did not confer a
survival benefit over placebo in the Sudden
Cardiac Death in Heart Failure Trial (SCD-HeFT)
of symptomatic heart failure patients with LVEF
of 35% or less [45].
Amiodarone plus beta-blockers was shown to
be superior to monotherapy with sotalol or
beta-blockers in the OPTIC trial for the
reduction of shocks in secondary prevention
ICD recipients [19]. As a result of its greater
efficacy, amiodarone is the most common
antiarrhythmic agent used for suppression of
VT in patients with structural heart disease and
ICDs. In the AVID trial, nearly twice as many
patients in the ICD arm who ultimately received
adjuvant antiarrhythmic therapy were treated
with amiodarone compared to either sotalol or
mexiletine [17].
Amiodarone has a low risk of proarrhythmia,
despite causing prolongation of the action
potential duration and QT interval, probably
because it reduces heterogeneity of
depolarization. Torsade de pointes occurred in
less than 1% in the EMIAT and CAMIAT trials
[46, 47]. Extracardiac toxicity, however, is well
described, and is related to both a daily and
cumulative dose effect of amiodarone. Clinical
hypothyroidism occurs in up to 32% of patients,
and may require thyroxine supplementation
even after drug discontinuation [22].
Hyperthyroidism can also occur, but is less
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iodine intake is adequate. Pulmonary toxicity is
less common but is among the most serious
adverse drug reactions, presenting as chronic
interstitial pneumonitis, bronchiolitis obliterans
with organizing pneumonia, or the acute
respiratory distress syndrome. Corneal deposits,
skin photosensitivity, neuropathy, and
gastrointestinal side effects have also been
reported [22].
Sotalol
Sotalol is a potassium channel blocker that
prolongs action potential duration and is a
Vaughan Williams Class III agent. It is a racemic
mixture of D-sotalol, which has pure Class III
antiarrhythmic activity, and L-sotalol, which
has Class III and beta-blocker effects. Doses less
than 120 mg twice daily appear to have a
primary beta-blocker effect, with higher doses
producing significant Class III activity [22].
A placebo-controlled trial in 302 ICD
recipients showed that treatment with racemic
sotalol significantly reduced the risk of death or
ICD shock (34% incidence with sotalol vs. 54%
with placebo) at 1 year [32]. However, the rate of
drug discontinuation in the sotalol arm was 27%.
A similar finding was noted in the OPTIC trial,
with nearly a quarter of patients discontinuing
sotalol therapy due to drug intolerance [19]. The
most common adverse reactions in these trials
were related to the beta-blocking effects of the
drug; symptomatic bradycardia and torsade de
pointes were rare. Of note, in the Survival With
Oral D-Sotalol (SWORD) trial, D-sotalol, which
does not have significant beta-blocking effects,
was associated with increased mortality and
proarrhythmia in patients with post-MI left
ventricular dysfunction [33].
The most significant adverse reaction
associated with sotalol is torsade de pointes,
seen in 2–3% of patients; especially at risk are
women and patients with heart failure or
chronic kidney disease (because of its
significant renal drug elimination) [48]. For
this reason, it is common practice to initiate
sotalol therapy in the inpatient setting with
continuous ECG monitoring during the loading
phase for five doses in patients at higher risk. QT
interval prolongation and bradycardia can
presage the development of proarrhythmia and
may warrant a reduction of the sotalol dose.
Other adverse effects include fatigue,
bronchospasm, dyspnea and heart failure.
Unlike amiodarone, these effects are related to
the daily dose but not the cumulative dose,
making sotalol a more attractive first-line
therapy for younger patients or those for
whom longer-term treatment is anticipated [22].
Class I Antiarrhythmic Agents
The Cardiac Arrhythmia Suppression Trial (CAST)
compared Class IC agents to placebo in post-MI
patients with impaired LVEF (40% or less) for the
suppression of ventricular ectopy, and was
terminated prematurely due to excess mortality
in the antiarrhythmic arm [35]. Both all-cause
mortality and arrhythmic death were increased
with both encainide and flecainide treatment. As
such, Class IC antiarrhythmic agents are no
longer recommended therapy for patients with
ischemic heart disease or left ventricular
dysfunction from any cause. Conversely, the risk
of ventricular proarrhythmia with Class IC agents
in the absence of structural heart disease is low;
however, in patients with atrial arrhythmias,
flecainide or propafenone may promote 1:1
atrioventricular nodal conduction with
acceleration of the ventricular rate and a wide
QRS tachycardia [21].
Earlier studies that examined Class I agents
for secondary VT/VF prevention in post-MI
patients showed they were inferior in efficacy
to both amiodarone and sotalol [49, 50]. The
36 Cardiol Ther (2013) 2:27–46
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most commonly used Class I agent in this
setting is mexiletine, used in 20% of patients
who received adjuvant antiarrhythmic
treatment in the ICD arm of the AVID trial
[17]. As a Class IB antiarrhythmic agent, it does
not seem to carry the increased mortality risk
associated with the Class IC drugs, based on
observational data with the Class IB drug
lidocaine from the Global Utilization of
Streptokinase and TPA for Occluded Coronary
Arteries (GUSTO-I and GUSTO-IIb) trials [51].
Quinidine, procainamide, and disopyramide
are Class IA antiarrhythmic agents that have
intermediate sodium channel blocker activity
(compared to Class IC agents) and also prolong
action potential duration via potassium
channel blockade. They are indicated in the
treatment of supraventricular arrhythmias and
VT. Unfortunately, use of these agents is limited
by the risk of torsade de pointes (seen in
0.5–8%) and the poor tolerability of these
agents, including drug-induced lupus with
procainamide, anticholinergic effects with
disopyramide, and a host of gastrointestinal,
dermatologic and neurologic side effects seen
with quinidine use [21].
While the lower efficacy and poor
tolerability of the Class I agents has relegated
them to third-line therapy for the prevention
and treatment of ventricular arrhythmia, there
is evidence that combination therapy with a
Class I and a Class III agent may be more
effective than monotherapy with either
agent [43]. Common combinations include
amiodarone or sotalol plus mexiletine.
Emerging Antiarrhythmic Therapy
Dronedarone
Dronedarone is a recent addition to the
antiarrhythmic armamentarium. A Vaughan
Williams Class III agent, dronedarone is a
multichannel blocker similar in structure to
amiodarone but noniodinated. It was
developed with the potential to achieve
antiarrhythmic efficacy similar to that of
amiodarone, without the extracardiac toxicity
seen with long-term amiodarone therapy [26,
52]. It is approved for the treatment of atrial
fibrillation, largely based on results of A Trial
With Dronedarone to Prevent Hospitalization or
Death in Patients With Atrial Fibrillation
(ATHENA), a placebo-controlled, double-blind,
parallel arm trial to assess the efficacy of
dronedarone 400 mg b.i.d. for the prevention
of cardiovascular hospitalization or death from
any cause in patients with atrial fibrillation or
atrial flutter, which demonstrated significant
reductions in the composite endpoint of
all-cause mortality and cardiovascular
hospitalization with dronedarone vs. placebo
[26]. In two earlier randomized trials of
dronedarone in patients with atrial fibrillation
or flutter, rates of pulmonary, thyroid, and
hepatic adverse effects were not significantly
greater with dronedarone than with placebo at
1 year follow-up [27]. After its approval in the
United States, however, subsequent reports of
severe liver toxicity led to a warning by the US
Food and Drug Administration, recommending
that prescribing physicians follow hepatic
function tests routinely [53].
Although dronedarone has not been studied
specifically for the treatment of VT/VF, animal
studies have demonstrated antiarrhythmic
properties on ventricular myocardium, and
subsequent reports in humans have supported
its efficacy in select cases [54–56]. In addition,
in ATHENA, patients on dronedarone showed a
reduction in arrhythmic death [26]. The use of
dronedarone in patients with heart failure,
however, is controversial in light of the
Antiarrhythmic Trial with Dronedarone in
Moderate to Severe CHF Evaluating Morbidity
Cardiol Ther (2013) 2:27–46 37
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Decrease (ANDROMEDA) trial, whose results
suggest dronedarone may lead to worsening
heart failure symptoms and a two-fold increase
in mortality in this population [52]. As such,
dronedarone is contraindicated in Class IV heart
failure patients or in those who have had a recent
hospitalization for decompensated heart failure.
The ANDROMEDA study authors recommend
that ‘‘dronedarone should not be used in patients
with heart failure and reduced left ventricular
systolic function.’’ A more recent placebo-
controlled trial of dronedarone in patients with
permanent atrial fibrillation and major vascular
risk factors (including CAD and heart failure)
was stopped prematurely due to a two-fold
excess in cardiovascular mortality [57]. Stroke,
hospitalization for heart failure, and arrhythmic
deaths were also significantly increased in the
dronedarone arm of the Permanent Atrial
Fibrillation Outcome Study Using Dronedarone
on Top of Standard Therapy (PALLAS) [57]. While
some of these adverse findings were unexplained,
it was postulated that the negative inotropic
effects of dronedarone, along with its drug–drug
interactions (notably with vitamin K antagonists
and with digoxin) and potential proarrhythmic
effects, may have contributed.
In summary, while dronedarone has been
shown to be effective in suppressing ventricular
arrhythmia in animal studies and in case reports
of patients with refractory VT/VF episodes, the
results of ANDROMEDA and PALLAS have
raised doubts about the safety of this
medication in patients with structural heart
disease.
Dofetilide
Dofetilide is a Class III antiarrhythmic agent
and a selective blocker of the rapid delayed
rectifier potassium current, IKr [58]. It is
approved in North America for the treatment
of atrial fibrillation; however, it has been shown
to have efficacy in the treatment of ventricular
arrhythmia. A randomized trial of patients with
CAD and sustained VT showed that oral
dofetilide was equally as effective as oral
sotalol in the prevention of recurrent
ventricular arrhythmias and arrhythmic death
at 1 year [59]. A more recent study in 30 ICD
recipients with drug-refractory VT/VF episodes
showed a significant reduction in both monthly
ventricular arrhythmia episodes (from 1.8 ± 4.5
to 1.0 ± 3.5, P = 0.006) and monthly ICD
therapies (from 0.9 ± 1.4 to 0.4 ± 1.7,
P = 0.037) after treatment with dofetilide. In
addition, 83% of patients had complete
suppression of VT/VF during their first month
of treatment [60].
Dofetilide is very well tolerated, although
inpatient monitoring for 3 days is required
during the loading phase, given the risk of QT
prolongation and the potential for torsade de
pointes (seen in 1–3%) [23, 24]. Dofetilide
dosing is based on calculated creatinine
clearance, as a result of its renal drug
elimination. The safety of dofetilide has been
established in patients with left ventricular
dysfunction and CAD [24, 25], and on the
basis of limited clinical experience in the
treatment of ventricular arrhythmia, it may be
an alternative antiarrhythmic agent for such
patients with VT/VF events refractory to
amiodarone and/or sotalol therapy.
Ranolazine
Ranolazine is a novel antianginal drug with
multiple ion channel blocking antiarrhythmic
activity. It is a piperazine derivative with a
chemical structure similar to lidocaine, and its
most potent ion channel blocking effect is on
late sodium current [28, 29, 61, 62]. It is thus
considered a Vaughan Williams Class IB agent.
Ranolazine also has effects on the delayed
rectifier current (IKr) and prolongs action
38 Cardiol Ther (2013) 2:27–46
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potential duration, with corresponding QT
interval prolongation on electrocardiography.
It has been shown in experimental animal
models to have antiarrhythmic effects in the
ventricle [61, 62]. In the Metabolic Efficiency
With Ranolazine for Less Ischemia in
Non-ST-Elevation Acute Coronary Syndrome–
Thrombolysis in Myocardial Infarction 36 trial
(MERLIN-TIMI 36), ranolazine was shown
clinically to reduce arrhythmia episodes,
including nonsustained VT, on ambulatory
cardiac monitoring in patients presenting with
acute coronary syndrome [29]. It has
subsequently been used in the suppression of
ectopic ventricular activity [63] and for the
reduction in VT burden and prevention of
shocks in ICD recipients [64].
Ranolazine in particular works synergistically
with the Class III antiarrhythmic agents, most
commonly with amiodarone [65]. This has been
demonstrated in animal models to have an
antiarrhythmic effect in both the atrium and
ventricle. In rabbit hearts treated with both
ranolazine and a Class III agent, there was no
increase in early after-depolarizations or
ventricular proarrhythmia associated with the
addition of ranolazine [61]. In addition, in the
MERLIN-TIMI 36 trial, despite causing modest
QT prolongation, ranolazine use was not
associated with an increased risk of SCD
compared with placebo [66]. Based on limited
but positive clinical experiences with ranolazine,
it appears to be beneficial as add-on therapy in
patients with recurrent VT events while on a
Class III antiarrhythmic agent.
Azilimide
Azimilide is an investigational Class III
antiarrhythmic agent that blocks both the
rapid (IKr) and slow (IKs) components of the
delayed rectifier cardiac potassium current. It
causes prolongation of the atrial and ventricular
action potential duration and refractory period
[36]. As such, azimilide has demonstrated
action against both supraventricular and
ventricular arrhythmias. In the Shock
Inhibition Evaluation with Azimilide (SHIELD)
trial, a randomized controlled trial of 633
secondary prevention ICD recipients, the
primary endpoint of all-cause shocks plus
symptomatic tachyarrhythmias terminated
by antitachycardia pacing was significantly
reduced in patients receiving azimilide [36]. In
addition, the secondary endpoint of appropriate
ICD therapies for VT/VF episodes was reduced
by 48% and 62%, with the 75 mg and 125 mg
doses of azimilide, respectively.
Based on the concerning results from
previous antiarrhythmic drug trials in patients
with structural heart disease, such as CAST and
SWORD, azimilide was studied prospectively in
the Azimilide Postinfarct Survival Evaluation
(ALIVE) trial, in which 3,717 patients with
recent MI and an ejection fraction between
15% and 35% were randomly assigned to
receive azimilide, 100 mg daily, vs. placebo. At
1 year of follow-up, there were no significant
differences in all-cause, cardiac, or arrhythmic
mortality between the azimilide and placebo
groups [67].
Overall, azimilide was well tolerated in
clinical trials. In the SHIELD trial, its
discontinuation rate was similar to the placebo
arm. Adverse events with azimilide include
neutropenia (seen in 1% of patients) and QT
prolongation leading to torsade de pointes (seen
in up to 1–2% of patients). It is not currently
approved for use in North America or Europe.
Celivarone
Celivarone is a noniodinated benzofuran
derivative that is in investigational use for
its action against atrial and ventricular
arrhythmias [37]. Similar to amiodarone and
Cardiol Ther (2013) 2:27–46 39
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dronedarone, it has Class I, II, III and IV
antiarrhythmic activity, but with different
relative potencies for the various channels and
receptors. Also, its structure and kinetics differ
from those of amiodarone and lend itself to an
improved side effect profile and reduced
potential for drug interactions [68]. It was
shown in a small phase 2 clinical study of ICD
recipients to trend toward fewer VT and VF
episodes at the higher dose of celivarone
(300 mg daily), although the 46% relative risk
reduction at 6 months was not statistically
significant [69]. A larger trial of 486 patients
with LVEF of 40% or less and at least one VT/VF
episode within a month of enrollment,
however, did not find that celivarone was any
more effective for the prevention of ICD
interventions or sudden death than placebo
[68]. In both studies, celivarone was well
tolerated and had an acceptable safety profile.
Nonetheless, in light of the disappointing
clinical data to date, it is not currently
approved for use in humans.
Future Antiarrhythmic Targets
Novel targets for the treatment of ventricular
arrhythmia continue to be explored, and it is
likely that pharmacologic agents directed at some
of these targets will enter clinical trials in the next
few years. The commonly used antiarrhythmic
medications for VT/VF primarily target sodium
channels (Class I agents) or potassium channels
(Class III agents), but are limited by variable
efficacy and the potential for ventricular
proarrhythmia. Newer therapeutic approaches
to cardiac arrhythmias have focused on the
roles of intracellular calcium, gap junctions,
sodium–calcium exchange, and adenosine
triphosphate (ATP)-sensitive potassium channel
blockade, and will be reviewed briefly [37].
Intracellular Calcium
Altered intracellular calcium handling has been
implicated in ventricular arrhythmogenesis in a
number of models [6]. Two important proteins
in myocardial calcium homeostasis are the
sarcoplasmic reticulum (SR) calcium ATPase
(SERCA2a) and the ryanodine receptor (RyR2).
The former promotes calcium reuptake into the
SR and the latter is a SR calcium release channel
that promotes an increase in cytosolic calcium,
which in turn activates myocardial contractile
proteins. Diastolic calcium leakage via RyR2 is
thought to contribute to proarrhythmia,
notably by promoting after-depolarizations in
the cardiomyocyte. CPVT is one cardiac
electrical disorder characterized by leaky
RyR2, resulting in delayed after-depolarizations
and polymorphic VT triggered by exercise
and adrenergic stimulation [6, 41]. The
antiarrhythmic agent flecainide targets RyR2,
and was shown to prevent arrhythmias in a
mouse model of CPVT, by inhibiting RyR2-
mediated calcium release. Now this agent has
found a role clinically to suppress VT events in
patients with CPVT in conjunction with beta-
blockers [70].
Pharmacotherapies to normalize intracellular
calcium handling by either stabilizing RyR2
activity or modulating associated proteins
involved in diastolic SR calcium leakage in
order to prevent arrhythmia may prove to be
novel antiarrhythmic agents in the future. In a
recent report, a pharmacologic RyR2 stabilizer
was investigated in both a mouse model and in
human nonfailing myocardium, and was found
to be effective in reducing SR calcium leak [71].
Another recent report showed that inhibition of
calcium/calmodulin-dependent kinase (CaMKII)
was able to reduce cardiac arrhythmias and SCD
in a proarrhythmic mouse model similar to that
seen in CPVT [72].
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Gap Junctions
Cell–cell coupling in the heart acts to maintain
synchronization of depolarization and
repolarization between myocytes, and
disruption of this coupling is thought to
contribute to arrhythmogenesis. It has been
proposed that restoration or enhancement of
coupling via gap junctions may be an effective
antiarrhythmic target [37]. Connexin 43 is the
principal gap junction protein responsible for
cell–cell coupling in ventricular myocardium,
and its function is impaired during acute
ischemia and acidosis [73]. Rotigaptide, an
antiarrhythmic peptide that improves
conduction across gap junctions, has been
shown in experimental animal models to
suppress ischemia-induced proarrhythmia [73].
The proposed mechanism of action of rotigaptide
is prevention of the dephosphorylation of
connexin 43 that accompanies acute metabolic
stress. By maintaining gap junction conductance,
this peptide in turn both prevents conduction
slowing in the cardiomyocytes, and synchronizes
the action potentials thereby reducing dispersion
of refractoriness [74].
While the concept of normalizing gap
junction conductance with an antiarrhythmic
agent is a promising one, there are multiple
mechanisms by which gap junction physiology
can be impaired in disease states other than by
dephosphorylation. The roles of myocyte
fibrosis, connexin protein downregulation and
trafficking in the remodeling of gap junctions
have all been appreciated and may pose
challenges to the development of a single
pharmacotherapeutic target or agent [73].
Sodium–Calcium Exchange
The sodium–calcium exchanger (NCX) is the
primary pathway for intracellular calcium
removal in the cardiomyocyte. It is a cell
membrane protein that removes a single
calcium ion in exchange for the import of
three sodium ions, while operating in the
forward mode. Increased expression or activity
of NCX has been associated with impaired
cardiac contractility and an increased risk of
arrhythmias in the setting of heart failure [75].
NCX also operates in the reverse mode,
promoting intracellular calcium loading,
during conditions of high cytosolic sodium
concentration, or in the setting of digitalis use
(which antagonizes the sodium/potassium
ATPase). Excessive calcium loading can also be
proarrhythmic, as it promotes triggered activity
through delayed after-depolarizations [6, 75].
NCX blockade has been considered to be a
potential therapeutic strategy for cardiac
arrhythmias, in particular with agents that
predominantly inhibit the reverse mode over the
forward mode. To date, there has been limited
progress in the development of clinically useful
agents. Two drugs, KBR-7943 and SEA-0400, have
been shown to prevent calcium overload in
models of ischemia/reperfusion injury, and
appear to reduce after-depolarizations in models
of vulnerable cardiac tissue [75]. These findings
are promising but await further in vivo
confirmation in animal models.
ATP-Sensitive Potassium Channel Blockade
Myocardial ischemia is associated with increases
in extracellular potassium, which is believed to
contribute to ventricular proarrhythmia. The
activation of cardiac cell membrane ATP-
sensitive potassium channels during myocardial
ischemia promotes potassium efflux and
reductions in action potential duration;
impaired function of the sodium/potassium
ATPase may also contribute [76]. In addition,
ischemia-induced potassium accumulation is
heterogeneous, which leads to dispersion of
repolarization and thereby creates a substrate
for reentrant arrhythmias.
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ATP-sensitive potassium channel activity is
inhibited by ATP but activated by adenosine 50-
diphosphate (ADP). Therefore, with a fall in the
ATP:ADP ratio during myocardial ischemia, the
ATP-sensitive potassium channel opens and
potassium leaves the cell. Increases in
extracellular potassium are known to promote
perturbations in cardiac electrical activity, such
as increased excitability of normal ventricular
tissues, leading to premature ventricular
complexes, and a reduction in action potential
duration. Regional dispersion of the refractory
period, especially during periods of myocardial
ischemia, is a major contributor to the
development of VF. Glibenclamide is an ATP-
sensitive potassium channel inhibitor that has
been shown to attenuate reductions in action
potential duration in models of ischemia, and
suppress extrasystoles and VF [76].
Glibenclamide is a sulfonylurea that also
provokes hypoglycemia due to its effects on
noncardiac tissue [76]. For ATP-sensitive
potassium channel inhibition to become an
attractive therapeutic option, cardioselective
pharmaceuticals must be developed and
tested. Currently, the agents HMR-1883, HMR-
1098 and HMR-1402 have been developed and
studied in animals, with favorable results on the
reduction of ischemic cardiac arrhythmias [77].
CONCLUSION
In patients with structural heart disease at risk of
ventricular arrhythmias, the ICD continues to be
the gold standard therapy for the reduction of
SCD and improved long-term survival.
Antiarrhythmic medication is indicated as add-
on therapy in those with VT events to reduce the
morbidity associated with recurrent arrhythmic
episodes. While amiodarone and sotalol are the
principal agents used in this setting, their use is
often limited by suboptimal effectiveness and
drug intolerance or toxicity leading to
discontinuation.
Newer and emerging antiarrhythmic
therapies must meet the challenge of
effectively suppressing drug-refractory VT/VF
without promoting proarrhythmia or other
cardiovascular adverse events. While dofetilide
and ranolazine hold promise, and merit further
investigation in large prospective studies of ICD
patients, dronedarone use in atrial fibrillation
has been associated with a disturbing signal of
harm in patients with structural heart disease.
Therefore its use in patients with VT should be
carefully considered or avoided in the absence
of prospective data establishing its safety and
efficacy in this population. Azimilide and
celivarone await more convincing efficacy data
in humans before they are approved for clinical
use.
A better understanding of the molecular
mechanisms of ventricular arrhythmogenesis
has provided basic electrophysiologists with
new antiarrhythmic targets related to
intracellular calcium handling, gap junctions,
sodium–calcium exchange, and ATP-sensitive
potassium channel activity. Further advances in
this field will undoubtedly spur novel drug
therapies for patients with refractory ventricular
arrhythmias in the future.
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